Details for Patent: 11,052,084
✉ Email this page to a colleague
Which drugs does patent 11,052,084 protect, and when does it expire?
Patent 11,052,084 protects CAPLYTA and is included in one NDA.
This patent has eleven patent family members in ten countries.
Summary for Patent: 11,052,084
| Title: | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
| Abstract: | The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease. |
| Inventor(s): | Li; Peng (New Milford, NJ), Davis; Robert (San Diego, CA) |
| Assignee: | INTRA-CELLULAR THERAPIES, INC. (New York, NY) |
| Application Number: | 16/903,133 |
|
Patent Claim Types: see list of patent claims | Use; Compound; Process; Dosage form; |
Drugs Protected by US Patent 11,052,084
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 11,052,084 | ⤷ Subscribe | Y | TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS | ⤷ Subscribe | |||
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 11,052,084 | ⤷ Subscribe | Y | TREATMENT OF SCHIZOPHRENIA MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS | ⤷ Subscribe | |||
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-003 | Apr 22, 2022 | RX | Yes | No | 11,052,084 | ⤷ Subscribe | Y | TREATMENT OF SCHIZOPHRENIA MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS | ⤷ Subscribe | |||
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-003 | Apr 22, 2022 | RX | Yes | No | 11,052,084 | ⤷ Subscribe | Y | TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,052,084
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019331490 | ⤷ Subscribe | |||
| Brazil | 112021003838 | ⤷ Subscribe | |||
| Canada | 3108558 | ⤷ Subscribe | |||
| China | 112584838 | ⤷ Subscribe | |||
| European Patent Office | 3843739 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
